Skip to main content

Healthy Participants Study

4
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Candid Therapeutics
Candid TherapeuticsCA - San Diego
2 programs
2
CND319Phase 11 trial
cizutamigPhase 11 trial
Active Trials
NCT07712939Recruiting105Est. Mar 2028
NCT07236411Completed24Est. Jul 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD0292Phase 11 trial
Active Trials
NCT06311760Completed32Est. Feb 2025
Kymera Therapeutics
Kymera TherapeuticsMA - Watertown
1 program
1
KT-621Phase 11 trial
Active Trials
NCT06673667Completed118Est. Apr 2025
Parexel
ParexelMA - Boston
1 program
AnifrolumabPHASE_1Monoclonal Antibody
Prothena
ProthenaDUBLIN 2, Ireland
1 program
PRX019PHASE_11 trial
Active Trials
NCT06699680Completed50Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
Candid TherapeuticsCND319
Candid Therapeuticscizutamig
ProthenaPRX019
Kymera TherapeuticsKT-621
AstraZenecaAZD0292

Clinical Trials (5)

Total enrollment: 329 patients across 5 trials

NCT07712939Candid TherapeuticsCND319

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

Start: Jul 2026Est. completion: Mar 2028105 patients
Phase 1Recruiting
NCT07236411Candid Therapeuticscizutamig

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Start: Dec 2025Est. completion: Jul 202624 patients
Phase 1Completed
NCT06699680ProthenaPRX019

Phase 1 Study of PRX019 in Healthy Adult Volunteers

Start: Nov 2024Est. completion: Jan 202650 patients
Phase 1Completed
NCT06673667Kymera TherapeuticsKT-621

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

Start: Oct 2024Est. completion: Apr 2025118 patients
Phase 1Completed
NCT06311760AstraZenecaAZD0292

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Start: Apr 2024Est. completion: Feb 202532 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 329 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.